Supplemental material
Report
Influence of the bispecific antibody IgG subclass on T cell redirection
, , 
, , &
Ricardo M. AttarOncology Biology & Discovery, Janssen Research and Development, Spring House, PA,USAhttps://orcid.org/0000-0002-6942-8019View further author information
https://orcid.org/0000-0002-6942-8019View further author information, , & Related Research Data
Novel immunotherapies in lymphoid malignancies.
Source:
Springer Science and Business Media LLC
Structural variations, chemical modifications and possible impacts to stability and biological function
Source:
Informa UK Limited
Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor
Source:
Springer Science and Business Media LLC
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Source:
Proceedings of the National Academy of Sciences
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Radius of gyration as an indicator of protein structure compactness
Source:
Pleiades Publishing Ltd
In-depth analysis of subclass-specific conformational preferences of IgG antibodies
Source:
International Union of Crystallography
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.
Source:
American Society of Hematology
Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3
Source:
Proceedings of the National Academy of Sciences
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Source:
Nature Publishing Group
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
Source:
Impact Journals, LLC
Constant domains influence binding of mouse-human chimeric antibodies to the capsular polypeptide of Bacillus anthracis.
Source:
Informa UK Limited
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma
Source:
American Society of Hematology
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
Source:
Proceedings of the National Academy of Sciences
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
Source:
Springer Science and Business Media LLC
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Source:
American Society of Hematology
IgG Fc engineering to modulate antibody effector functions
Source:
SpringerOpen
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
Source:
Informa UK Limited
Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses
Source:
Elsevier BV
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses
Source:
Wiley
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
Source:
Springer Science and Business Media LLC
Bispecific abs for Treatment of PCa
Source:
Wiley
Bispezifische Antikörper
Source:
Elsevier BV
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Source:
Springer Science and Business Media LLC
GD2-BsAb redirects T cells to target tumors
Source:
Wiley
Mechanisms for T cell receptor triggering
Source:
Springer Science and Business Media LLC
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Source:
American Society of Hematology
The making of bispecific antibodies
Source:
Taylor & Francis
“NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
Source:
Informa Healthcare
FDA Approval: Blinatumomab.
Source:
American Association for Cancer Research (AACR)
Linking provided by
